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CORRESPONDENCE
Letters to the Editor
Spontaneous Late
Closure of Patent Foramen Ovale
The study by Meissner et al. (1) and the accompanying editorial by
Meier (2) provide contrasting views concerning the pathologic
significance of patent foramen ovale (PFO). A large autopsy study
from the Mayo Clinic (3) showed a decreasing incidence of PFO
with age that the investigators attributed to late spontaneous
closure, although they did not suggest the mechanism whereby this
might occur. Meier (2) proposes an alternative explanation, namely
that the presence of a PFO is associated with a reduced life
expectancy. Meissner et al. (1) and Siostrzonek et al. (4) note that
a PFO is less frequently detected in patients with elevated left atrial
pressure, but they imply that this is the result of a lower sensitivity
of the detection technique rather than a lower incidence of PFO.
We believe it unlikely that a PFO confers a significant mortality
disadvantage. If this were the case then one would expect a lower
proportion of larger PFOs with age as large PFOs are considered
to confer a higher risk of adverse events (2). Hagen et al. (3) found
the reverse. We believe a more plausible explanation is that a
chronically elevated left atrial pressure as occurs with advancing
age and loss of left ventricular compliance (5) can result in late
closure of a PFO, particularly if small. Indirect evidence for this
assumption comes from an observation that in a personal series
(R.W.H.) of 260 consecutive patients with mitral stenosis under-
going percutaneous trans-septal valvuloplasty, a PFO was crossed
only twice. In this procedure the foramen ovale is always probed
with a catheter stiffened with the trans-septal needle. Accordingly,
if a PFO had been present in these patients with the same
incidence as in the general population (25%), one would have
expected a much higher crossing rate than was observed (1%). In
an otherwise normal heart it is generally very easy to cross a PFO
with a catheter directed at the limbus of the fossa ovalis.
We believe that the likely explanation for the low crossing rate
in mitral stenosis is that the chronically elevated left atrial pressure
associated with this condition results in closure of a PFO. We also
believe that the lower detection rate of PFO in conditions with
elevated left atrial pressure may be the result of late closure of the
PFO rather than an inability to detect the condition.
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Patent Foramen Ovale and
the Risk of Cryptogenic Stroke
We would like to congratulate Meissner et al. on their impressive
cohort study of patent foramen ovale (PFO) and stroke. However,
we hold significant reservations on the stated conclusion that PFO
is not an independent risk factor for future cerebrovascular events
in the general population (1).
The population studied by Meissner et al. (1) was predomi-
nately elderly, with a mean age of nearly 70 years ( 13 years). The
association of PFO and stroke is much less conclusive in older
populations, with conflicting studies (2,3). Increasing age is asso-
ciated with increasing incidence of traditional risk factors for
atheroembolic stroke—clearly demonstrated in this study where
over 50% of subjects were hypertensive and over 50% had visible
aortic plaque (1). It is likely that mechanisms other than paradox-
ical embolism predominate in these older age groups. The plausi-
bility of a congenital defect suddenly causing a cerebrovascular
ischemic event is intuitively much less.
Additionally, it appears no attempt was made to identify those
ischemic strokes that were considered “cryptogenic.” These repre-
sent the minority of the total strokes (4), but they have been most
often associated with PFO (5).
The management of PFO and cryptogenic stroke is an evolving
area (6). There are currently at least 3 recruiting trials of PFO
closure versus medical management. Of note, all specify an upper
age limit for enrollment of 60 years (7–9). The results of these
trials are eagerly awaited.
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REPLY
The comment by Harper and Haqqani, namely that a patent
foramen ovale (PFO) is unlikely to confer a significant mortality
disadvantage, indirectly acknowledges that it might. Paradoxical
embolism through a PFO can unequivocally have devastating
consequences, including death. Hence, even if no significant risk
for mortality has yet been proven, people die from it (1). This must
suffice to take the matter seriously. If there was a simple vaccina-
tion to close the PFO, it would be a world standard. Implantation
of a device in the heart, with an inherent risk for mortality as well,
needs proof of superiority over the natural course. This proof (or
disproof) is subject to time. About 1,000 patients have been
randomized between device closure and natural course in a variety
of trials in progress. Device implantation should show any disad-
vantage quite early as its risks are front-loaded. An advantage,
however, takes many years to unveil because events from a PFO are
fortunately rare (rarer than we initially thought), but not absent.
None of the trials has been stopped prematurely, which speaks
against a disadvantage without compromising the hope for an
advantage of PFO closure.
The theory of selective mortality of the PFO is indeed not in
keeping with the finding that the fewer PFOs in the elderly are
larger in size (2). The theory of late spontaneous fusion by
increasing left atrial pressure with age could explain that. Con-
versely, there is hard evidence for the first theory (people do die
from PFOs) but not for the second. The fact that patients with
mitral stenosis had a passable PFO in 1% according to Harper
and Haqqani is not sufficiently explained by either theory. The
bulging of the atrial septum into the right atrium in mitral stenosis
is likely to render catheter passage from the inferior vena cava more
difficult as the PFO is hidden behind this bulge in a region where
the septum now is tangential to the catheter path, making probing
for the PFO unyielding. Many PFOs go undetected under these
circumstances, although they are not fused but simply functionally
closed by elevated left atrial pressure and moved out of target for
access from the inferior vena cava.
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REPLY
We appreciate and acknowledge the interest in our recently reported
study (1). In regard to the comments of Schrale et al., we studied
subjects in age increments or “cells” of 10 years beginning at age 45,
and we did not find an increased stroke risk in even the younger age
cells. A recent case control study published by Petty et al. (2) supports
our finding that patent foramen ovale (PFO) does not appear to be a
risk factor for cryptogenic stroke in the general population.
Also, Harper and Haqqani provide intriguing thoughts regard-
ing the issue of PFO detection rates in older individuals. It is
possible that a PFO may close in older subjects, but this postulate
is based on many assumptions, including that older people have
elevated left atrial pressures. This is an interesting concept that
merits systematic evaluation.
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Coronary Plaque Burden
and Cardiovascular Risk Factors:
Single-Point Versus Serial Assessment
In their interesting study, Nicholls et al. (1) recently assessed in a
large series of patients the relation between various cardiovascular
risk factors and the amount of coronary plaque burden with
(non-serial) volumetric intravascular ultrasound (IVUS). In this set
of high-quality data, male gender, diabetes mellitus, and a history
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